Zhexiang Li, MD
Internal Medicine · Florham Park, NJNPI 1710929898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 301 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.
Across 301 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$771
- Novo Nordisk$554
- Bayer$467
- Astellas Pharma US Inc$417
- AstraZeneca$362
- Boehringer Ingelheim$341
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$4,68495%
- Education$2555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 56 | $771 |
| Novo Nordisk | 33 | $554 |
| Bayer | 25 | $467 |
| Astellas Pharma US Inc | 15 | $417 |
| AstraZeneca | 26 | $362 |
| Boehringer Ingelheim | 16 | $341 |
| Merck | 18 | $240 |
| Pfizer | 17 | $238 |
| AbbVie(2 entities) | 21 | $207 |
| Exact Sciences | 9 | $202 |
| GSK | 10 | $168 |
| Pharming Healthcare, Inc. | 1 | $130 |
| Corcept Therapeutics | 1 | $108 |
| Otsuka America Pharmaceutical, Inc. | 6 | $95 |
| Abbott | 5 | $82 |
| Johnson & Johnson | 6 | $75 |
| Nestle Healthcare Nutrition Inc. | 4 | $55 |
| Amgen | 4 | $53 |
| Currax Pharmaceuticals LLC | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $43 |
| Biogen | 3 | $39 |
| Novartis | 3 | $39 |
| Mylan Specialty L.p. | 2 | $28 |
| IBSA Pharma Inc. | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $25 |
| Althera Pharmaceuticals LLC | 2 | $23 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,953 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 71 | $62,494 |
| EliquisApixaban | 104 | $58,054 |
| OzempicSemaglutide | 17 | $44,821 |
| FarxigaDapagliflozin Propanediol | 31 | $40,531 |
| MounjaroTirzepatide | 29 | $40,438 |
| XareltoRivaroxaban | 83 | $37,368 |
| JanuviaSitagliptin Phosphate | 33 | $32,887 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $26,146 |
| MyrbetriqMirabegron | 38 | $17,920 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,817 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 55 | $17,550 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 63 | $13,333 |
| Valsartan | 259 | $8,991 |
| VascepaIcosapent Ethyl | 11 | $6,656 |
| Rosuvastatin Calcium | 305 | $6,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Paxlovid | $238 | $78,463175 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $341 | $68,65183 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Shingrix | $168 | $57,297140 claims |
| Novo NordiskOzempic | $554 | $44,82117 claims |
| AstraZenecaFarxiga | $362 | $40,53131 claims |
| Lilly USA, LLCMounjaro | $771 | $40,43829 claims |
| Johnson & JohnsonXarelto | $75 | $37,36883 claims |
| MerckJanuvia | $240 | $32,88733 claims |
| Astellas Pharma US IncMyrbetriq | $417 | $17,92038 claims |
| AbbVieLumigan | $207 | $4,74818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Florham Park
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.